Roberto M. Lemoli

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 136 publications

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026

Severe hypereosinophilia and eosinophilic myocarditis during secondary plasma cell leukemia: evidence of a paraneoplastic manifestation of aggressive myeloma evolution.

Severe hypereosinophilia and eosinophilic myocarditis during secondary plasma cell leukemia: evidence of a paraneoplastic manifestation of aggressive myeloma evolution.

Journal: Annals of hematology
Published: June 08, 2026

Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.

Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.

Journal: Cancers
Published: April 14, 2026

Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications.

Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications.

Journal: Leukemia & lymphoma
Published: March 07, 2026

Counting the Cost: Anticipated Financial Burden and Post-Traumatic Stress Symptoms in Patients Newly Diagnosed with Leukemia and Lymphoma.

Counting the Cost: Anticipated Financial Burden and Post-Traumatic Stress Symptoms in Patients Newly Diagnosed with Leukemia and Lymphoma.

Journal: Mediterranean journal of hematology and infectious diseases
Published: January 15, 2026

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer
Published: December 16, 2025

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: December 04, 2025

Long-term health-related quality of life and lifestyle behavior of patients with acute myeloid leukemia.

Long-term health-related quality of life and lifestyle behavior of patients with acute myeloid leukemia.

Journal: The oncologist
Published: September 23, 2025

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Journal: Annals of hematology
Published: August 30, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: July 29, 2025

The protective role of HCWs communication for the distress of newly diagnosed people with leukemia and lymphoma.

The protective role of HCWs communication for the distress of newly diagnosed people with leukemia and lymphoma.

Journal: PEC innovation
Published: June 11, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances
Published: May 19, 2025
Showing 1-12 of 136

Last Updated: 09/26/2026